Clinical Research Directory
Browse clinical research sites, groups, and studies.
SGLT2 Inhibitors and Renal Anemia in Japan: RWD
Sponsor: Boehringer Ingelheim
Summary
The objectives of the study are: 1. To evaluate the association between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor use and the occurrence of anemia in patients with chronic kidney disease (CKD) using a nested case-control design with incidence density sampling. 2. To evaluate anemia-related outcomes using a nested case-control-based analytical framework, including assessment of within-subject changes in anemia-related treatments and healthcare costs by comparing the period after study entry with the period after the index date (for cases) or matched reference date (for controls), and comparison according to SGLT2 inhibitor use: A) Prescription patterns and treatment regimens for anemia, including analysis of medication types, dosing strategies, and duration of treatments B) Anemia-related healthcare costs C) Change in laboratory values
Official title: Effect of SGLT2 Inhibitors on Renal Anemia and Its Management in Patients With CKD in Japan
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
15000
Start Date
2025-07-23
Completion Date
2026-12-25
Last Updated
2026-05-08
Healthy Volunteers
No
Conditions
Interventions
SGLT2 inhibitor
SGLT2 inhibitor
Locations (1)
Nippon Boehringer Ingelheim Co ., Ltd.
Tokyo, Japan